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Introduction
============

Cardiovascular (CV) disease and cancer are the cause of about two-thirds of all deaths worldwide.[@sux019-B1] Due to the progressive aging of the population the eventuality that a same individual may be affected by both, CV and cancer, is not uncommon.[@sux019-B2]The association, indeed, is not casual, cancer and heart diseases may share the same risk factors,[@sux019-B3] and such chance is amplified by cardiovascular complication of oncologic therapy that can lead to premature morbidity and death of cancer survivors.[@sux019-B4] The above considerations have led to the development of a new branch of clinical cardiology: the cardio-oncology,[@sux019-B5] a discipline based on the collaboration among cardiologists, oncologists and other medical specialists in order to find solutions for the prevention, monitoring, diagnosis and treatment of heart damage before, during and after antitumour treatments (*Figure [1](#sux019-F1){ref-type="fig"}*). In this Executive Summary we point out the major key points in order to achieve the most effective cancer treatment, while minimizing the risk of cardiac toxicity.

![The collaborative model in cardio-oncology. The realization of a management strategy to effectively treat cancer and minimize the risk of cardiac damage provides for close multidisciplinary collaboration between the different actors involved in patient management. The cooperation is particularly necessary in the presence of a patient with a structural heart disease or a high CV risk and with potentially cardiotoxic care plan.](sux019f1){#sux019-F1}

The assessment of the cardiovascular risk
=========================================

Many oncologic drugs have cardiotoxic effects[@sux019-B4] (*Table [1](#sux019-T1){ref-type="table"}*) often exacerbated by the presence of a pre-existing heart disease (clinical or subclinical) or by the presence of traditional CV risk factors.[@sux019-B4] The estimation of CV risk profile of patients (*Table [2](#sux019-T2){ref-type="table"}*) is valuable in cardio-oncology and should be integrated with data related to tumour treatment, in order to improve the choice on the most appropriate chemotherapy protocol and on the best cardio-protective therapy as well as to perform the most appropriate monitoring measures to schedule the follow-up. The CV risk factors should be treated with appropriate primary and secondary prevention measures according with the most recent guidelines on cardiovascular prevention of the European Society of Cardiology (ESC).[@sux019-B6]Table 1Antineoplastic agents and their cardiotoxic effect^6^ClassIndication\*IncidenceDrugArrhythmiasQT elongationSystolic dysfunctionHypertensionMyocardial ischaemiaThrombo- embolismAnthracyclinesDaunorubicinLeukemia ++/ +++✓+---------AdriamicinBreast, Lymphomas, Sarcomas+/ ++✓ ++/ +++------✓Liposomial adriamicinLymphomas, Sarcomas+✓---+/ ++/ +++EpirubicinBreast, Stomach---✓+/ ++------✓IdarubicinLeukemia ++/ +++✓ ++/ +++------✓MitoxantroneLeukemia ++/ +++✓ ++/ +++ ++ ++---Alkylating agentsCisplatinoBladder, HNC, Lung, Ovary✓✓✓✓✓ ++CyclophosphamideHemat. Breast------✓------+IfosfamideCervix Sarcomas✓--- +++------+Antimicrotubules agentsDocetaxelBreast Lung+/ ++✓ ++ ++ ++✓Nab-PaclitaxelBreast Pancreas+/ ++✓---------+PaclitaxelBreast Lung ++✓+---+---AntimetabolitesCapecitabineColon-Rectum Breast✓✓✓--- +++/ ++5-FluorouracilGastrointestinal✓✓+--- ++/ +++✓Hormone therapyAbirateroneProstate ++--- ++ ++/ +++ ++---AnastrozoleBreast--------- ++/ +++ ++ ++ExemestaneBreast--------- +++LetrozoleBreast--------- ++ ++/ +++ ++TamoxifenBreast---✓--- ++/ +++ ++ ++Target therapy with monoclonal antibodyBevacizumabColon-Rectum Breast ++✓+/ ++ ++/ ++++/ ++ ++/ +++BrentuximabLymphomas------------+ ++CetuximabColon-Rectum HNC ++---✓ ++✓+/ ++IpilimumabMelanoma------------------PanitumumabColon-Rectum✓------ ++ +++PertuzumabBreast------ ++---------RituximabHemat.✓------ ++ ++ ++/ +++TrastuzumabBreast Stomach ++--- ++/ +++ ++---+/ ++Target therapy with small moleculesBortezomibMultiple myeloma+---+/ +++++Dasatinib (TKI)Leukemia ++/ ++++/ ++ ++ ++ +++/ ++Erlotinib (TKI)Lung✓--------- ++ ++Gefitinib (TKI)Lung✓✓------+/ ++✓Imatinib (TKI)CMC------+/ ++--- ++++Lapatinib (TKI)Breast✓ +++ ++---------Nilotinib (TKI)CMC ++ ++ ++ ++✓+Pazopanib (TKI)RCC------+ ++++/ ++ ++Sorafenib (TKI)RCC, HCC+✓+ +++ ++ ++Sunitinib (TKI)GIST, RCC++ ++/ +++ +++ +++/ ++Vemurafenib (TKI)Melanoma ++✓+ ++ ++ ++MiscellaneaEverolimusRCC------ ++ ++---+LenalidomideMultiple myeloma+/ +++ ++ ++ ++ ++/ +++TemsirolimusRCC---✓--- ++ +++ ++[^1]Table 2Patient-related risk factors for cardiotoxicityWhat to lookWhat to evaluateHow to treatKnown heart diseasePresent/absent[^a^](#tblfn2){ref-type="table-fn"}Implement primary/secondary prevention measures provided for by the GuidelinesPrior exposure to cardiotoxic chemotherapy and/or mediastinal radiotherapyPresent/absent[^b^](#tblfn3){ref-type="table-fn"}In case of exposure in asymptomatic patient evaluate the cardiovascular status (ventricular function, silent ischaemia, valves disease)SmokePack/year[^c^](#tblfn4){ref-type="table-fn"}QuitAlcohol consumptionDaily UnitsAbstention o moderate use (1--4 U/die)Physical activityWeekly hoursEncourage mild to moderate aerobic activity (at least 3--5 h/week)Blood pressureHigh blood pressuresearch ventricular hypertrophyGive priority to drugs with proven cardioprotective action (ace-i/ARBs, beta-blockers)ObesityCalculate body mass indexweight reduction with the Mediterranean dietHigh blood sugarPost-prandial glycaemia (2 h) or glycated haemoglobin and blood glucose ≤ 125 mg/dL but\> 100 mg/dLImplement dietary program and exercise when carbohydrate intolerance, encourage the use of metformin in the case of type II diabetesAbdominal circumference[^d^](#tblfn5){ref-type="table-fn"}Establish whether there is metabolic syndromeImplement dietary program and exercise, treatment of dyslipidaemia and high blood pressureLipid profileTotal cholesterol, HDL cholesterol, triglyceridesImplement dietary program and exercise, statinsRenal function[^e^](#tblfn6){ref-type="table-fn"}Creatinine, eGFRLow-protein, low-salt diet, treat high blood pressure and dyslipidaemia[^2][^3][^4][^5][^6]

Heart failure
=============

Heart failure (HF) is a very common complication of antineoplastic treatments and may occur with several classes of anticancer drugs[@sux019-B7] (*Table [1](#sux019-T1){ref-type="table"}*). *Table [3](#sux019-T3){ref-type="table"}* shows the risk factors for anthracyclines cardiotoxicity that may lead also to late onset cardiomyopathy.[@sux019-B10]^,^[@sux019-B11] Other conventional chemotherapies, cyclophosphamide, cisplatin, ifosfamide, and taxanes (paclitaxel and docetaxel), can rarely induce left ventricular dysfunction (LVD) and HF. Immunotherapies and targeted therapies (*Table [1](#sux019-T1){ref-type="table"}*) can, also, cause LVD and HF. Moreover, concomitant use of anthracyclines with trastuzumab, a monoclonal antibody directed against the receptor HER2/ErbB2, especially in cancer patients with high CV risk, may lead to severe cardiotoxicity effects.[@sux019-B7]^,^[@sux019-B12]^,^[@sux019-B13] Nevertheless, trastuzumab-related cardiomyopathy is not dependent on cumulative dose and is considered to be reversible upon treatment discontinuation and proper therapy.[@sux019-B9] The cardiotoxicity risk of other anti-HER2/ErbB2 targeted agents (lapatinib, pertuzumab, and trastuzumab-emtansine) appears to be similar to that of trastuzumab.[@sux019-B9]Table 3Risk factors of anthracyclines cardiotoxicityRisk factorCumulative dose (life-span)Total cumulative dose (Adriamycin\> 450 mg/m^2^; epirubicin\> 900 mg/m^2^) markedly increases the risk in the long-term cardiotoxicityDuration of follow-upThe risk increases with prolonged survival for doses\>250 mg/m^2^Rate of administrationThe risk of acute cardiotoxicity is lower withslow rate of infusionIndividual doseSingle high doses increase the risk of late onset toxicityType of anthracyclineThe liposomal anthracyclines are less cardiotoxicityRadiotherapyPrior or concomitant administration (\>30 Gy) increases the risk of cardiotoxicityComplementary chemotherapyTrastuzumab, bevacizumab, paclitaxel, alkylating agents (cyclophosphamide, ifosfamide, melphalan), bleomycin, vincristine, paclitaxel, docetaxelPre-existing cardiovascular risk factorsHypertension, ischaemic heart disease, valvular heart disease, previous cardiotoxic treatmentsComorbidityDiabetes mellitus, chronic obstructive pulmonary disease, renal dysfunction, liver failure, obesity, dysthyroidism, electrolyte disorders, sepsisAgeYoung and old are at greatest riskSexWomen are at greater risk than menAdditional factorsTrisomy 21 and African American race are at greater risk

Vascular endothelial growth factor (VEGF) inhibitors can cause reversible or irreversible cardiac side effects: arterial hypertension is the most frequent, with potential LVD and HF.

Management
----------

Cardiotoxic cardiomyopathy is difficult to treat and has a relatively poor prognosis if not promptly diagnosed.[@sux019-B14] Among the imaging techniques, a predominant role is played by echocardiography, a non-invasive, repeatable, available and relatively inexpensive technique.[@sux019-B9] The ejection fraction (EF) is the echocardiographic parameter most frequently used to monitor heart health. Significant declines of EF often may occur at a later time with irreversible cardiac damage. One of the aims of clinical research is to find the best technique able to identify the early cardiac damage before it produces alterations of the common ventricular contractility indexes, and then before the cardiac damage becomes irreversible (*Table [4](#sux019-T4){ref-type="table"}*). In the recent years, Global Longitudinal Strain (GLS) technique, assessed using automated speckle-tracking echocardiography (STE), has emerged for detecting and quantifying LVD. A drop of 10% from baseline is very largely abnormal and may represent subclinical dysfunction in order to consider cardioprotection also in patients without the classic criteria of cardiotoxicity (LVEF \< 50%).It has been largely demonstrated that this technique is very promising to monitor the effects of cardioprotection. Table 4Summary table of the instrumental parameters used to identify the damage from chemotherapyMethod usedParameterDiagnostic values for cardiotoxicityLimitsEchocardiographyEjection fraction (EF)\* Decrease\>5% with EF \< 55% if symptomatic patient for heart failure (HF)\* Image quality (better with ultrasound contrast agent)\* Decrease\>10% with EF \< 55% if asymptomatic patient\* Dependence on the haemodynamic state\* Intra- and inter-operator variability (better with 3D-echo)\* Late and irreversible alterationsDobutamine stress-echoEF Fractional shortening (FS)\* Reduction of EF and/or FS during pharmacological stress\* Consistent results but from small and not confirmed studiesDoppler EchocardiographyDiastolic parameters: isovolumetric relaxation time (IVRT), deceleration time (DT), E, e', E/A ratio,\* Diastolic dysfunction (↑ IVRT and DT, ↓ E, e\' and E/A ratio)\* Discordant data on the predictive power of future dysfunction\* Not recommended for monitoringTissue Doppler Imaging (TDI)Mitral annulus velocity (s\') septal and lateral\* Reduction below 15 cm/sec (septal) and 20 cm/sec (lateral)\* Discordant data between different studies\* Frequent reduction ofs\' in pts with prior chemotherapy, without development of HFTwo-dimensional Speckle Tracking echocardiographyGlobal longitudinal strain\* Reduction of \> 15% from baseline within days after chemotherapy seems to predict future decline in EF\* Need for dedicated software\* Results still to be confirmed on a large scaleCardiac magnetic resonance (CMR), dynamic sequences without contrastLV and RV volumes and EF\* Improved accuracy and reproducibility in identifying drops in EF\* Costs\* Availability on the territoryCMR, delayed sequences after contrast agent (gadolinium)Early (oedema) and late (fibrosis) enhancement\* Intramyocardial oedema seen during therapy with trastuzumab and ↓ FE\* Results regarding prognostic significance of oedema and fibrosis to be confirmed on a large scale\* Fibrosis is associated with poor prognosis

*Biomarkers* (*Table [5](#sux019-T5){ref-type="table"}*), also, may be used as 'red flags' to encourage a close clinical and instrumental monitoring and treatment. The same biomarker assay may be used for continued screening throughout the treatment pathway and substantial increases during follow-up may anticipate asymptomatic LVD in high CV risk patient treated with potentially cardiotoxic chemotherapy. Nevertheless at present the evidence to establish the interpretation of subtle variation is insufficient and their role as exclusive method for routinely surveillance of cardiac damage is not clearly ascertained. Table 5Biomarkers and risk stratificationMarker typePopulation studiedFindings and observationsTnT, TnI, hsTnTAnthracyclines: baseline measurement, at the end of the infusion, and one month after chemotherapy\* High predictive value (mostly negative) in the high-dose anthracyclines\* Maybe poor prognostic factor in medium and low dosesTnT, TnI, hsTnTTrastuzumab for metastatic breast cancer: baseline survey, 2 and 4 months after starting treatment\* It seems to anticipate about 2 months the development of systolic dysfunction\* Increased positive predictive value when combined with declining global longitudinal strain\* Results to be confirmed in larger studiesBPN, Nt-proBNPAnthracyclines (breast cancer): before and after treatment\* A \> 36% increase from baseline seems to correlate with LV systolic dysfunction\* Mixed results in different studiesBNP, Nt-proBNPTrastuzumab\* Few studies, mixed results

Strategies for reducing cardiotoxicity
--------------------------------------

In the absence of definite treatments that can reverse the anthracyclines-related myocardial damage, it is important to identify new treatment strategies that prevent or minimize the potential cardiotoxic side effects (*Table [6](#sux019-T6){ref-type="table"}*), especially in high risk patients (*Table [3](#sux019-T3){ref-type="table"}*) that require a strict control of traditional CV risk factor. Table 6Strategies to control the risk of cardiotoxicityType of strategyAdvantagesOnly retrospective studiesWeekly infusions (instead of three times a week)Lower blood peaks, observed incidence of heart failure 0.8% (vs. 2.9% with traditional scheme)Only retrospective studiesProlonged infusion (\>6 h) instead of rapid bolusLower blood peaks, reduced incidence of heart failureNeed for central venous access, with increase of costs, preparation time and care, risk of infectionEpirubicinBetter tolerance compared with doxorubicin.Higher costs of doxorubicinLiposomal anthracyclines (pegylated or non-pegylated)Lower volume of distribution, with greater concentration on the neoplastic tissue\* Not available studies directly comparing with free doxorubicin.less cardiotoxicityIron chelating agents (dexrazoxane)Protective effect on acute cardiotoxicity\* Not available data on the protective effect of late toxicityCurrently only indicated for patients with metastatic breast cancer previously treated with high doses of anthracyclines\* Equivocal increase of seconds in the long run tumours

Ischaemic heart disease
=======================

Radiation therapy as well as many cancer drugs can induce myocardial ischaemia[@sux019-B4]^,^[@sux019-B7]^,^[@sux019-B9] (*Tables [1](#sux019-T1){ref-type="table"}*and*[7](#sux019-T7){ref-type="table"}*). Table 7Chemotherapy associated with ischaemia (Modified by 14)DrugIncidence5-Fluorouracil1--68%Capecitabine3--9%Paclitaxel\<1--5%Sunitinib/Sorafenib2.3%Erlotinib2.3%Bevacizumab0.6--1.7%Axitinib1--2%Pazopanib2%Ponatinib3--20%

Fluoropyrimidine and capecitabine
---------------------------------

Asymptomatic ST-segment changes on ECG represents the most frequent cardiotoxic manifestation (55%). Chest pain with or without ST-segment changes is the common clinical complaint (45%) and evolution in acute coronary syndrome may occur. Patients should be closely monitored for myocardial ischaemia using regular ECG. The symptoms usually occur within the first 72 h of 5-fluorouracil (5-FU) infusion and in the first 6 days of initiation in the case of oral administration of capecitabine.[@sux019-B15] Occasionally, 5-FU and Capecitabine toxicity appear as acute heart failure and Tako-tsubo syndrome with LVD, in such case ventricular arrhythmias and sudden death may occur. Ischaemic heart disease can also be a complication of antiangiogenic agents: bevacizumab and tyrosine kinase inhibitors (sunitinib, sorafenib, ponatinib, axitinib, pazopanib, regorafenib).[@sux019-B9] Coronary artery disease may be a late complication of high radiation doses to mediastinum.

Management
----------

In the case of fluoropyrimidine toxicity, chemotherapy should be stopped and patients hospitalized in coronary intensive care if acute coronary syndrome is suspected. The administration of non-dihydropyridine calcium channel blockers (verapamil or diltiazem) and nitrates may be indicated for the frequent occurrence of coronary spasm. If there is an absolute indication on drug rechallenge, the treatment should be performed with half dose and the patients monitored closely. The association of calcium channel blockers therapy may be useful.

Arrhythmias
===========

In cancer patients Heart Rhythm Disturbances (HRD) may be the result of multiple risk factors. Metabolic disorders, electrolyte disturbances, medications (e.g. antihistamines, antiemetic, anti-infective, psychotropic drugs) can affect the appearance of cardiac arrhythmias. Nevertheless, HRD are more frequent with some chemotherapies (*Tables [1](#sux019-T1){ref-type="table"}*and*[8](#sux019-T8){ref-type="table"}*). A 12-lead ECG should be recorded and the QT interval, corrected for heart rate with Bazett's or Fridericia's formula, should be obtained in all patients at baseline. Treatment should be interrupted or alternative regimens considered if the QTc is \>500 ms, QTc prolongation is \>60 ms or arrhythmias are present. Factors as hypokalaemia, hypomagnesiemia, extreme bradycardia, and QT-prolonging drugs should be minimized inpatients treated with potential QT-prolonging chemotherapy (*Figure [2](#sux019-F2){ref-type="fig"}*).

![Algorithm for the evaluation and management in the course of chemotherapy with potential effect on the QT.](sux019f2){#sux019-F2}

Table 8Arrhythmias and related mechanisms of action induced by chemotherapy drugsAritmiaFarmacoMeccanismo d'azioneBradycardiaPaclitaxelInterference with His-Purkinje systemTalidomideHyper-reactivity to Cremophor EL (with release of histamine)Vaso-vagal stimulation↓TNFα and inhibition of the neurons of the nucleus of the vagusHyperactivity of the parasympathetic systemHypothyroidismQT prolongationArsenic trioxideBlock of the potassium channelsTyrosine kinase inhibitorsCalcium overload (due to oxidative stress)DasatinibApoptosisLapatinibFragmentation of DNANilotinibBlock of the potassium channels (encoded by the HERG gene)SunitinibVandetanibPazopanibVemurafenibVorinostatAnthracyclinesVentricular fibrillationCapecitabineCoronary artery spasmKounis Syndrome

Arterial hypertension
=====================

Hypertension is a frequent co-morbidity in patients with cancer and may be worsened or newly induced by steroids o non-steroid anti inflammatory drugs frequently used in oncology. Antiangiogenetic agents (*Table [1](#sux019-T1){ref-type="table"}*) can induce hypertension and degenerate to related heart complications (i.e. heart failure, myocardial ischaemia). ACE inhibitors or ARBs, beta-blockers and dihydropyridine calcium channel blockers are the antihypertensive drugs of choice. Non-dihydropyridine calcium channel blockers should preferably be avoided due to drug interactions.

Thrombo-embolic disease
=======================

Thrombo-embolism often complicates the course of cancer and recognizes different aetiological moments (*Table [9](#sux019-T9){ref-type="table"}*). The arterial thrombotic events (ETA) in cancer can occur in case of treatment with anti-angiogenic drugs, cisplatin, VEGF inhibitors, and hormonal therapies. Ischaemia/myocardial infarction is the most common clinical manifestation. The pro-thrombotic state may facilitate embolic events secondary to atrial fibrillation. The most frequent thrombo-embolic complications in cancer patients are venous thrombo-embolism (VTE) with deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is the second cause of death in cancer patients. It may affect up to 20% of hospitalized patients and is frequently undiagnosed. A four weeks antithrombotic therapy with low molecular weight heparin (LMWH) is currently recommended for VTE prophylaxis by consensus guidelines.[@sux019-B9] In the case of major surgery, systematic prophylaxis for VTE in outpatient admitted for chemotherapy is not recommended and the decision should be individualized. In stable patients LMWH given over a period of 3--6 months is the first choice for TVE therapy in cancer patients. At the moment we do not have enough data to support the use of fondaparinux or new oral anticoagulants (NOAC) for the initial treatment of acute VTE in patients with cancer. We are waiting the results of Hokusai VTE-cancer to know if edoxaban is similar to dalteparin in preventing recurrence of acute VTE following and initial index in cancer subjects.[@sux019-B15] Different NOACs may differ because of potential drug interactions and sensitivity to renal or hepatic dysfunction. The use of vitamin K antagonists (VKA) in cancer patients is complicated; difficulties in maintaining a therapeutic International Normalised Ratio (INR) occur due to a variety of reasons such as drug interactions, unpredictable bioavailability, vomiting, malnutrition or diarrhea, poor compliance for repeated laboratory tests. Table 9Risk factors and biomarkers associated with thrombosis in cancerCancer-related factorsTreatment-related factorsPatient-related factorsBiomarkersPrimary site of Tumour (pancreas, brain, stomach, kidney, lung, lymphoma, myeloma)Advanced Stage (metastatic)Histology(\>adenocarcinoma)Initial period after diagnosis(3--6 months)Major Surgery (abdomen, pelvis)ChemotherapyAntioangiogenetic Agents (Lenalidomide, Talidomide, Bevacizumab)Hormone Therapyerythropoiesis-stimulating factors (ESA), transfusion; central venous catheters (CVC); duration of surgery \> 30', radiotherapy (RT)Old AgeGender (Female \> Male)African ethnicityComorbidities (infections, renal dysfunction, pulmonary disease, atherosclerotic disease)Inherited prothrombotic MutationsObesityHistory of thombo-embolic diseasePoor performance status (PPS)Platelet Count ≥ 350000,White Blood Cells count\> 11000Haemoglobin (Hb) \<10 g/dLhigh levels of D-dimer,high level of soluble P-selectin,high level of C-reactive protein

Surveillance in the follow-up
=============================

Cancer patients follow-up is critical for the prevention and treatment of possible late cardiovascular complications (*Table [10](#sux019-T10){ref-type="table"}*). Table 10Suggested follow-up and treatment after cancer therapyTreatment performedExams programmedAssociated risk factorsAnthracyclines,Echocardiogramparticularly if:At 6--12 month of follow-up, after completion of chemotherapyHypertensionFemaleAge \<15 years or \> 60 yearsDose (Doxorubicin\> 240 mg/mq; Epirubicin \>360 mg/mq)Every 1--5 years, depending on the risk profileDyslipidaemiaDiabetes mellitusObesitySedentarySmokeTarget therapy ± TaxanesYearly for 5 years after the conclusion of therapy. Thereafter every 5 yearsAlcohol consumptionHormone therapyClinical follow-upKidney failureRadiation therapy to the chest/mediastinalEchocardiography at 6--12 month of follow-up, then every 1--5 years depending on risk profileif involved the left hemithorax and/or total radiation in the cardiacExercise test after 5 years and then every 3--5 years.area ≥ 30GyConsider Stress-Echocardiography or coronary CT scanRadiation therapy to the head/neckCarotid artery Echo-Doppler after 3--5 years Ultrasound thyroid and periodic evaluation of thyroid hormones (FT3, FT4, TSH)

Cancer patients should be aware on the possible cardiovascular risk factors, overall subjects treated with anthracyclines or mediastinal radiotherapy. At 10 years it is mandatory to perform stress test or CT coronary angiography[@sux019-B16] (*Figure [3](#sux019-F3){ref-type="fig"}*). Moreover, patients should be encouraged to a healthy lifestyle. A careful surveillance is often necessary for the patients in long-term hormonal therapy. Tamoxifen may increase the risk of thrombo-embolic complications and aromatase inhibitors have been linked to increased risk of heart disease The same applies to patients treated with androgen deprivation therapy (ADT) for prostate cancer which are prone to metabolic syndrome, diabetes, accelerated atherosclerosis, and cardiovascular events.

![Algorithm of patient management during and after radiation.](sux019f3){#sux019-F3}
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[^1]: \*, Selected examples on the frequency of use of the drug; +++, \>10%; ++, 1--10%; +, \<1% or rare; ✓, observed but the precise incidence has not been well established; ---, complication not reported; CML, chronic myeloid leukemia; GIST, gastrointestinal stromal tumour; HCC, hepatocellular carcinoma; Emat., haematological; HF, heart failure; HNC, cancer of the head and neck; RCC, carcinoma of the kidney; TKI, tyrosine kinase inhibitor.

[^2]: ^a^Define the type, severity and clinical stability in relation to the oncology care program.

[^3]: ^b^'Life span' threshold of high-risk: prior anthracyclines exposure (adriamycin 250--300 mg/m^2^ epirubicin 600--800 mg/m); radiation exposure (35--50 Gy). In the case of radiation define whether he was involved the left hemithorax.

[^4]: ^c^Is obtained by multiplying the number of cigarette packs (20 cigarettes) smoked per day by the number of years of smoking.

[^5]: ^d^\>102 cm men; \>90 cm in women.

[^6]: ^e^Renal dysfunction = eGFR \<60 ml/min.
